Chengliu Lv
Fujian Medical University Union Hospital, No. 29 Xinquan Street
Fuzhou, 350000, China
Fuzhou, 350000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Efficacy and safety of PD-1 inhibitors plus chemotherapy with or without endostatin for stage IV lung squamous cancer: a retrospective study.
Journal: Frontiers in immunology
Published: April 06, 2024
Impact of the number of lymph node dissections and a novel risk stratification on the prognosis in elderly locally advanced esophageal adenocarcinoma.
Journal: Journal of Cancer
Published: March 23, 2024
Ribosomal protein L22 like 1: a promising biomarker for lung adenocarcinoma.
Journal: Journal of Cancer
Published: November 01, 2023
Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
Journal: Frontiers in immunology
Published: September 19, 2023
LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab.
Journal: Annals of medicine
Published: September 15, 2023
First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study.
Journal: Annals of medicine
Published: August 09, 2023
The identification of genes associated T-cell exhaustion and construction of prognostic signature to predict immunotherapy response in lung adenocarcinoma.
Journal: Scientific reports
Published: January 13, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026